Miruna Dragomir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Miruna Dragomir has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Autier
International Prevention Research Institute (IPRI), Lyon, France
3 shared publications - Alina Macacu
International Prevention Research Institute, Lyon, France
2 shared publications Mathieu Boniol
International Prevention Research Institute, Lyon, France; University of Strathclyde Institute of Global Public Health at the International Prevention Research Institute, Lyon, France
2 shared publications- Peter Boyle
International Prevention Research Institute (IPRI), Lyon, France
2 shared publications - Alice Koechlin
International Prevention Research Institute (IPRI), Lyon, France
1 shared publication Celeste Lebbé
1 shared publication
Latest Publications
- Open Access
- 1 January 2020
- Published by Termedia Sp. z.o.o. in Journal of Health Inequalities
- Vol. 6 (1) , 63-74
Global burden of prostate cancer: regional disparities in incidence, mortality, and survival
Objectives This article aims to provide a comprehensive overview of the worldwide burden of prostate cancer by exploring its global incidence, mortality, and survival. Material and methods Incidence rates were extracted from the CI5plus and NORDCAN databases. Prostate cancer deaths and...
- 1 January 2020
- Published by Termedia Sp. z.o.o. in Journal of Health Inequalities
- Vol. 6 (1) , 63-74
Open AccessGlobal burden of prostate cancer: regional disparities in incidence, mortality, and survival
Objectives This article aims to provide a comprehensive overview of the worldwide burden of prostate cancer by exploring its global incidence, mortality, and survival. Material and methods Incidence rates were extracted from the CI5plus and NORDCAN databases. Prostate cancer deaths and...
- Top Cited Papers
- 1 December 2017
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 5 (12) , 986-1004
Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials
- 1 December 2017
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 5 (12) , 986-1004
Top Cited PapersEffect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials
- 24 August 2017
- Published by Springer Nature in Acta Diabetologica
- Vol. 54 (11) , 983-991
Physical activity and change in fasting glucose and HbA1c: a quantitative meta-analysis of randomized trials
A systematic review was conducted of randomized trials which evaluated the impact of physical activity on the change in fasting glucose and HbA1c.
- 24 August 2017
- Published by Springer Nature in Acta Diabetologica
- Vol. 54 (11) , 983-991
Physical activity and change in fasting glucose and HbA1c: a quantitative meta-analysis of randomized trials
A systematic review was conducted of randomized trials which evaluated the impact of physical activity on the change in fasting glucose and HbA1c.
- Open Access
- 15 September 2015
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (12) , djv264
Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients
A low 25-hydroxyvitamin D3 (25(OH)D3) serum concentration at melanoma diagnosis might be associated with worse survival. We prospectively studied the prognostic value of 25(OH)D3 at diagnosis and during follow-up. MelanCohort is a cohort of invasive melanoma patients. Serum 25(OH)D3 was measured by mass spectrometry and standardized on month of blood drawn, age, sex, and body mass index (BMI). Role of 25(OH)D3 levels and risk of relapse was analyzed in a Cox proportional hazards model adjusting for age, sex, BMI, and American Joint Committee on Cancer (AJCC) stage. All statistical tests were two-sided. One thousand one hundred seventy-one patients were included. 25(OH)D3 levels at diagnosis (median = 49.0 nmol/L) were inversely correlated with prognostic factors such as AJCC stage (P < .001 Kruskal-Wallis), Breslow’s thickness (P < .001 Spearman correlation), and ulceration (P < .001 Kruskal-Wallis), but not with risk of relapse. Changes in 25(OH)D3 levels during follow-up were associated with worse prognosis: With a third quartile Q3 of average change per year (-0.30 to 4.60 nmol/L/Y) used as reference, hazard ratios for the first, second, and fourth quarters were 1.94 (95% confidence interval [CI] = 1.36 to 2.76), 1.23 (95% CI = 0.85 to 1.78), and 1.61 (95% CI = 1.14 to 2.28), respectively. In sensitivity analyses, no changes were observed either by AJCC stage, number of 25(OH)D3 measures performed, or by 25(OH)D3 level at baseline. No evidence of reverse causation was identified. Analyses performed on overall survival yielded similar results. We show that 25(OH)D3 variation during follow-up is an independent melanoma prognostic marker, but not its level at diagnosis. Previously reported associations between low 25(OH)D3 level at diagnosis and poor prognosis seem to be due to insufficient adjustment for prognostic factors.
- 15 September 2015
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (12) , djv264
Open AccessPrognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients
A low 25-hydroxyvitamin D3 (25(OH)D3) serum concentration at melanoma diagnosis might be associated with worse survival. We prospectively studied the prognostic value of 25(OH)D3 at diagnosis and during follow-up. MelanCohort is a cohort of invasive melanoma patients. Serum 25(OH)D3 was measured by mass spectrometry and standardized on month of blood drawn, age, sex, and body mass index (BMI). Role of 25(OH)D3 levels and risk of relapse was analyzed in a Cox proportional hazards model adjusting for age, sex, BMI, and American Joint Committee on Cancer (AJCC) stage. All statistical tests were two-sided. One thousand one hundred seventy-one patients were included. 25(OH)D3 levels at diagnosis (median = 49.0 nmol/L) were inversely correlated with prognostic factors such as AJCC stage (P < .001 Kruskal-Wallis), Breslow’s thickness (P < .001 Spearman correlation), and ulceration (P < .001 Kruskal-Wallis), but not with risk of relapse. Changes in 25(OH)D3 levels during follow-up were associated with worse prognosis: With a third quartile Q3 of average change per year (-0.30 to 4.60 nmol/L/Y) used as reference, hazard ratios for the first, second, and fourth quarters were 1.94 (95% confidence interval [CI] = 1.36 to 2.76), 1.23 (95% CI = 0.85 to 1.78), and 1.61 (95% CI = 1.14 to 2.28), respectively. In sensitivity analyses, no changes were observed either by AJCC stage, number of 25(OH)D3 measures performed, or by 25(OH)D3 level at baseline. No evidence of reverse causation was identified. Analyses performed on overall survival yielded similar results. We show that 25(OH)D3 variation during follow-up is an independent melanoma prognostic marker, but not its level at diagnosis. Previously reported associations between low 25(OH)D3 level at diagnosis and poor prognosis seem to be due to insufficient adjustment for prognostic factors.